U.S. drugmaker Merck & Co said on Wednesday its human papillomavirus (HPV) vaccine for men has been approved by China's ...

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

This was the stock's second consecutive day of gains.

Merck & Co announced that its HPV vaccine has received approval from China's medical products administration for use in males aged 9-26 years. This marks a significant development in extending ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Truist Financial analyst Srikripa Devarakonda downgraded Merck & Company (MRK – Research Report) to a Hold yesterday and set a price target ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

WuXi Biologics, a Chinese biopharmaceuticals company, announced on Monday the sale of its WuXi Vaccines facility in Ireland ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...